Yu MC, Ross RK, Chan KK, et al. 1995. Glutathione S-transferase M1 genotype affects aminobiphenyl-hemoglobin adduct levels in white, black and Asian smokers and nonsmokers. *Cancer Epidemiol Biomarkers Prev* 4(8):861-4.

Zang EA, Wynder EL. 1992. Cumulative tar exposure. A new index for estimating lung cancer risk among cigarette smokers. *Cancer* 70(1):69-76.

PM3006857394

Source: https://www.industrydocuments.ucsf.edu/docs/tmlx0001

Tang D, Warburton D, Tannenbaum SR, Skipper P, Santella RM, Cereijido GS, Crawford FG, Perera FP. 1999. Molecular and genetic damage from environmental tobacco smoke in young children. *Cancer Epidemiol Biomarkers Prev* 8(5)427-31.

Thorne S, Mullen MJ, Clarkson P, Donald AE, Deanfield JE. 1998. Early endothelial dysfunction in adults at risk from atherosclerosis: different responses to L-arginine. *J Am Coll Cardiol* 32(1):110-6.

U.S. DHHS (U.S. Department of Health and Human Services). 1988. *Smoking and Health; A Report of the Surgeon General.* Washington, DC: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention.

U.S. DHHS (U.S. Department of Health and Human Services). 1994. *Preventing Tobacco Use Among Young People: A Report of the Surgeon General.* Washington, DC: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention.

van Delft JH, Baan RA, Roza L. 1998. Biological effect markers for exposure to carcinogenic compound and their relevance for risk assessment. *Crit Rev Toxicol* 28(5):477-510.

van Diemen PC, Maasdam D, Vermeulen S, Darroudi F, Natarajan AT. 1995. Influence of smoking habits on the frequencies of structural and numerical chromosomal aberrations in human peripheral blood lymphocytes using the fluorescence in situ hybridization (FISH) technique. *Mutagenesis* 10(6):487-95.

van Schooten FJ, Hillebrand MJ, van Leeuwen FE, et al. 1990. Polycyclic aromatic hydrocarbon-DNA adducts in lung tissue from lung cancer patients. *Carcinogenesis* 11(9):1677-81.

Velicer WF, Prochaska, JO, Rossi, JS, Snow, MG. 1992. Assessing Outcome in Smoking Cessation Studies. *Psychological Bulletin* 111(1): 23-41.

Vineis P, Bartsch H, Caporaso N, et al. 1994. Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. *Nature* 369(6476):154-6.

Vineis P, Porta M. 1996. Causal thinking, biomarkers, and mechanisms of carcinogenesis. *J Clin Epidemiol* 49(9):951-6.

Vutuc C, Kunze M. 1983. Tar yields of cigarettes and male lung cancer risk. *J Natl Cancer Inst* 71(3):435-7.

Wald NJ, Thompson SG, Law MR, Densem JW, Bailey A. 1989. Serum cholesterol and subsequent risk of cancer: results from the BUPA study. *Br J Cancer* 59(6):936-8.

Wang LE, Bondy ML, de Andrade M, et al. 2000. Gender difference in smoking effect on chromosome sensitivity to gamma radiation in a healthy population. *Radiat Res* 154(1):20-7.

Wei Q, Gu J, Cheng L, et al. 1996. Benzo(a)pyrene diol epoxide-induced chromosomal aberrations and risk of lung cancer. *Cancer Res* 56(17):3975-9.

Wei Q, Matanoski GM, Farmer ER, Hedayati MA, Grossman L. 1993. DNA repair and aging in basal cell carcinoma: a molecular epidemiology study. *Proc Natl Acad Sci U S A* 90(4):1614-8.

Wennmalm A, Benthin G, Granstrom EF, Persson L, Petersson AS, Winell S. 1991. Relation between tobacco use and urinary excretion of thromboxane A2 and prostacyclin metabolites in young men. *Circulation* 83(5):1698-704.

Wiencke JK, Kelsey KT, Varkonyi A, et al. 1995. Correlation of DNA adducts in blood mononuclear cells with tobacco carcinogen-induced damage in human lung. *Cancer Res* 55(21):4910-4.

Wiencke JK, Spitz MR, McMillan A, Kelsey KT. 1997. Lung cancer in Mexican-Americans and African-Americans is associated with the wild-type genotype of the NAD(P)H: quinone oxidoreductase polymorphism. *Cancer Epidemiol Biomarkers Prev* 6(2):87-92.

Wiencke JK, Thurston SW, Kelsey KT, et al. 1999. Early age at smoking initiation and tobacco carcinogen DNA damage in the lung. *J Natl Cancer Inst* 91(7):614-9.

Wilcox HB, Schoenberg JB, Mason TJ, Bill JS, Stemhagen A. 1988. Smoking and lung cancer: risk as a function of cigarette tar content. *Prev Med* 17(3):263-72.

Yakubovskaya MS, Spiegelman V, Luo FC, et al. 1995. High frequency of K-ras mutations in normal appearing lung tissues and sputum of patients with lung cancer. *Int J Cancer* 63(6):810-4.

Yamasaki E, Ames BN. 1977. Concentration of mutagens from urine by absorption with the nonpolar resin XAD-2: cigarette smokers have mutagenic urine. *Proc Natl Acad Sci U S A* 74(8):3555-9.

Source: https://www.industrydocuments.ucsf.edu/docs/tmlx0001

Ryberg D, Skaug V, Hewer A, et al. 1997. Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer risk. *Carcinogenesis* 18(7):1285-9.

SAMHSA (Substance Abuse and Mental Health Services Administration). 1998. National Household Survey on Drug Abuse: Population Estimates 1998. [Online]. Available: http:www.samhsa.gov/oasNHSDA/Pe1998/Pop98web1.htm#TopOfPage [accessed 2001].

Santella RM, Weston A, Perera FP, et al. 1988. Interlaboratory comparison of antisera and immunoassays for benzo[a]pyrene-diol-epoxide-I-modified DNA. *Carcinogenesis* 9(7):1265-9.

Schoket B, Phillips DH, Kostic S, Vincze I. 1998. Smoking-associated bulky DNA adducts in bronchial tissue related to CYP1A1 MspI and GSTM1 genotypes in lung patients. *Carcinogenesis* 19(5):841-6.

Scott FM, Modali R, Lehman TA, et al. 1997. High frequency of K-ras codon 12 mutations in bronchoalveolar lavage fluid of patients at high risk for second primary lung cancer. *Clin Cancer Res* 3(3):479-82.

Seeman P. 1995. Dopamine receptors. Bloom FE, Lupfer DJ, ed. *Psycopharmacology; 4th Generation of Progress*. New York: Raven Press. Pp. 295-302.

Shields PG, Harris CC. 2000. Cancer risk and low-penetrance susceptibility genes in gene-environment interactions. *J Clin Oncol* 18(11):2309-15.

Shields PG, Lerman C, Audrain J, et al. 1998. Dopamine D4 receptors and the risk of cigarette smoking in African-Americans and Caucasians. *Cancer Epidemiol Biomarkers Prev* 7(6):453-8.

Shimoda R, Nagashima M, Sakamoto M, et al. 1994. Increased formation of oxidative DNA damage, 8-hydroxydeoxyguanosine, in human livers with chronic hepatitis. *Cancer Res* 54(12):3171-2.

Sidransky D. 1997. Nucleic acid-based methods for the detection of cancer. *Science* 278(5340):1054-9.

Simpson AJ. 1997. The natural somatic mutation frequency and human carcinogenesis. *Adv Cancer Res* 71:209-40 .

Sjalander A, Birgander R, Rannug A, Alexandrie AK, Tornling G, Beckman G. 1996. Association between the p21 codon 31 A1 (arg) allele and lung cancer. *Hum Hered* 46(4):221-5.

Slupphaug G, Lettrem I, Myrnes B, Krokan HE. 1992. Expression of O6-methylguanine--DNA methyltransferase and uracil--DNA glycosylase in human placentae from smokers and non-smokers. *Carcinogenesis* 13(10):1769-73.

Smith CJ, McKarns SC, Davis RA, et al. 1996. Human urine mutagenicity study comparing cigarettes which burn or primarily heat tobacco. *Mutat Res* 361(1):1-9.

Soussi T, Dehouche K, Beroud C. 2000. p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. *Hum Mutat* 15(1):105-13.

Speit G, Hartmann A. 1999. The comet assay (single-cell gel test). A sensitive genotoxicity test for the detection of DNA damage and repair. *Methods Mol Biol* 113:203-12.

Spitz MR, Hsu TC, Wu X, Fueger JJ, Amos CI, Roth JA. 1995. Mutagen sensitivity as a biological marker of lung cancer risk in African Americans. *Cancer Epidemiol Biomarkers Prev* 4(2):99-103.

Spitz MR, Shi H, Yang F, et al. 1998. Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients. *J Natl Cancer Inst* 90(5):358-63.

Stellman SD, Garfinkel L. 1989. Lung cancer risk is proportional to cigarette tar yield: evidence from a prospective study. *Prev Med* 18(4):518-25.

Stern SJ, Degawa M, Martin MV, et al. 1993. Metabolic activation, DNA adducts, and H-ras mutations in human neoplastic and non-neoplastic laryngeal tissue. *J Cell Biochem Suppl* 17F:129-37.

Stubbe I, Eskilsson J, Nilsson-Ehle P. 1982. High-density lipoprotein concentrations increase after stopping smoking. *Br Med J (Clin Res Ed)* 284(6328):1511-3.

Sumida H, Watanabe H, Kugiyama K, Ohgushi M, Matsumura T, Yasue H. 1998. Does passive smoking impair endothelium-dependent coronary artery dilation in women? *J Am Coll Cardiol* 31(4):811-5.

Sunyer J, Munoz A, Peng Y, et al. 1996. Longitudinal relation between smoking and white blood cells. *Am J Epidemiol* 144(8):734-41.

Tang D, Santella RM, Blackwood AM, et al. 1995. A molecular epidemiological case-control study of lung cancer. *Cancer Epidemiol Biomarkers Prev* 4(4):341-6.

PM3006857396

Source: https://www.industrydocuments.ucsf.edu/docs/tmlx0001

Pelkonen O, Vahakangas K, Nebert DW. 1980. Binding of polycyclic aromatic hydrocarbons to DNA: comparison with mutagenesis and tumorigenesis. *J Toxicol Environ Health* 6(5-6):1009-20.

Peluso M, Airoldi L, Armelle M, et al. 1998. White blood cell DNA adducts, smoking, and NAT2 and GSTM1 genotypes in bladder cancer: a case-control study. *Cancer Epidemiol Biomarkers Prev* 7(4):341-6.

Perera FP. 1987. Molecular cancer epidemiology: a new tool in cancer prevention. *J Natl Cancer Inst* 78(5):887-98.

Phillips AN, Neaton JD, Cook DG, Grimm RH, Shaper AG. 1992. The leukocyte count and risk of lung cancer. *Cancer* 69(3):680-4.

Phillips DH. 1997. Detection of DNA modifications by the 32P-postlabelling assay. *Mutat Res* 378(1-2):1-12.

Phillips DH, Hewer A, Martin CN, Garner RC, King MM. 1988. Correlation of DNA adduct levels in human lung with cigarette smoking. *Nature* 336(6201):790-2.

Poli P, Buschini A, Spaggiari A, Rizzoli V, Carlo-Stella C, Rossi C. 1999. DNA damage by tobacco smoke and some antiblastic drugs evaluated using the Comet assay. *Toxicol Lett* 108(2-3):267-76.

Pressl S, Edwards A, Stephan G. 1999. The influence of age, sex and smoking habits on the background level of fish-detected translocations. *Mutat Res* 442(2):89-95.

Prevost V, Shuker DE. 1996. Cigarette smoking and urinary 3-alkyladenine excretion in man. *Chem Res Toxicol* 9(2):439-44.

Raggi P, Callister TQ, Cooil B, et al. 2000. Identification of patients at increased risk of first unheralded acute myocardial infarction by electron-beam computed tomography. *Circulation* 101(8):850-5.

Ramsey MJ, Moore DH, Briner JF, et al. 1995. The effects of age and lifestyle factors on the accumulation of cytogenetic damage as measured by chromosome painting. *Mutat Res* 338(1-6):95-106.

Randerath E, Miller RH, Mittal D, Avitts TA, Dunsford HA, Randerath K. 1989. Covalent DNA damage in tissues of cigarette smokers as determined by 32P-postlabeling assay. *J Natl Cancer Inst* 81(5):341-7.

Randerath K, Reddy MV, Gupta RC. 1981. 32P-labeling test for DNA damage. *Proc Natl Acad Sci U S A* 78(10):6126-9.

Rangemark C, Benthin G, Granstrom EF, Persson L, Winell S, Wennmalm A. 1992. Tobacco use and urinary excretion of thromboxane A2 and prostacyclin metabolites in women stratified by age. *Circulation* 86(5):1495-500.

Rebbeck TR. 1997. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. *Cancer Epidemiol Biomarkers Prev* 6(9):733-43.

Reddy MV, Randerath K. 1986. Nuclease P1-mediated enhancement of sensitivity of 32P-postlabeling test for structurally diverse DNA adducts. *Carcinogenesis* 7(9):1543-51.

Rennard SI, Daughton D, Fujita J, et al. 1990. Short-term smoking reduction is associated with reduction in measures of lower respiratory tract inflammation in heavy smokers. *Eur Respir J* 3(7):752-9.

Rojas M, Alexandrov K, Cascorbi I, et al. 1998. High benzo[a]pyrene diol-epoxide DNA adduct levels in lung and blood cells from individuals with combined CYP1A1 MspI/Msp-GSTM1*0/*0 genotypes. *Pharmacogenetics* 8(2):109-18.

Rojas M, Camus AM, Alexandrov K, et al. 1992. Stereoselective metabolism of (-)-benzo[a]pyrene-7,8-diol by human lung microsomes and peripheral blood lymphocytes: effect of smoking. *Carcinogenesis* 13(6):929-33.

Rosvold EA, McGlynn KA, Lustbader ED, Buetow KH. 1995. Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking. *Pharmacogenetics* 5(4):199-206.

Rothman N, Poirier MC, Baser ME, et al. 1990. Formation of polycyclic aromatic hydrocarbon-DNA adducts in peripheral white blood cells during consumption of charcoal-broiled beef. *Carcinogenesis* 11(7):1241-3.

Ryberg D, Kure E, Lystad S, et al. 1994. p53 mutations in lung tumors: relationship to putative susceptibility markers for cancer. *Cancer Res* 54(6):1551-5.

PM3006857397

Source: https://www.industrydocuments.ucsf.edu/docs/tmlx0001

Mills NE, Fishman CL, Scholes J, Anderson SE, Rom WN, Jacobson DR. 1995. Detection of K-ras oncogene mutations in bronchoalveolar lavage fluid for lung cancer diagnosis. *J Natl Cancer Inst* 87(14):1056-60.

Mohrenweiser HW, Jones IM. 1998. Variation in DNA repair is a factor in cancer susceptibility: a paradigm for the promises and perils of individual and population risk estimation? *Mutat Res* 400(1-2):15-24.

Mohtashamipur E, Norpoth K, Lieder F. 1985. Isolation of frameshift mutagens from smokers' urine: experiences with three concentration methods. *Carcinogenesis* 6(5):783-8.

Mooney LA, Santella RM, Covey L, et al. 1995. Decline of DNA damage and other biomarkers in peripheral blood following smoking cessation. *Cancer Epidemiol Biomarkers Prev* 4(6):627-34.

Morrow JD, Frei B, Longmire AW, et al. 1995. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. *N Engl J Med* 332(18):1198-203.

Mustonen R, Hemminki K. 1992. 7-Methylguanine levels in DNA of smokers' and non-smokers' total white blood cells, granulocytes and lymphocytes. *Carcinogenesis* 13(11):1951-5.

Mustonen R, Schoket B, Hemminki K. 1993. Smoking-related DNA adducts: 32P-postlabeling analysis of 7-methylguanine in human bronchial and lymphocyte DNA. *Carcinogenesis* 14(1):151-4.

Nakajima T, Elovaara E, Anttila S, et al. 1995. Expression and polymorphism of glutathione S-transferase in human lungs: risk factors in smoking-related lung cancer. *Carcinogenesis* 16(4):707-11.

Nakayama J, Yuspa SH, Poirier MC. 1984. Benzo(a)pyrene-DNA adduct formation and removal in mouse epidermis in vivo and in vitro: relationship of DNA binding to initiation of skin carcinogenesis. *Cancer Res* 44(9):4087-95.

Nemeth-Coslett R, Griffiths RR. 1984. Determinants of puff duration in cigarette smokers: I.*Pharmacol Biochem Behav* 20(6):965-71.

Noble EP, St Jeor ST, Ritchie T, et al. 1994. D2 dopamine receptor gene and cigarette smoking: a reward gene? *Med Hypotheses* 42(4):257-60.

Nowak J, Murray JJ, Oates JA, FitzGerald GA. 1987. Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. *Circulation* 76(1):6-14.

O'Hara P, Connett JE, Lee WW, Nides M, Murray R, Wise R. 1998. Early and late weight gain following smoking cessation in the Lung Health Study. *Am J Epidemiol* 148(9):821-30.

O'Malley PG, Taylor AJ, Jackson JL, Doherty TM, Detrano RC. 2000. Prognostic value of coronary electron-beam computed tomography for coronary heart disease events in asymptomatic populations. *Am J Cardiol* 85(8):945-8.

Obe G, Vogt HJ, Madle S, Fahning A, Heller WD. 1982. Double-blind study on the effect of cigarette smoking on the chromosomes of human peripheral blood lymphocytes in vivo. *Mutat Res* 92(1-2):309-19.

Olincy A, Young DA, Freedman R. 1997. Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. *Biol Psychiatry* 42(1):1-5.

Oyama T, Kawamoto T, Mizoue T, et al. 1997. Cytochrome P450 2E1 polymorphism as a risk factor for lung cancer: in relation to p53 gene mutation. *Anticancer Res* 17(1B):583-7.

Park JW, Cundy KC, Ames BN. 1989. Detection of DNA adducts by high-performance liquid chromatography with electrochemical detection. *Carcinogenesis* 10(5):827-32.

Parry H, Cohen S, Schlarb JE, et al. 1997. Smoking, alcohol consumption, and leukocyte counts. *Am J Clin Pathol* 107(1):64-7.

Parsons WD, Carmella SG, Akerkar S, Bonilla LE, Hecht SS. 1998. A metabolite of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in the urine of hospital workers exposed to environmental tobacco smoke. *Cancer Epidemiol Biomarkers Prev* 7(3):257-60.

Pastorelli R, Guanci M, Cerri A, et al. 1998. Impact of inherited polymorphisms in glutathione S-transferase M1, microsomal epoxide hydrolase, cytochrome P450 enzymes on DNA, and blood protein adducts of benzo(a)pyrene-diolepoxide. *Cancer Epidemiol Biomarkers Prev* 7(8):703-9.

Patrick DL, Cheadle A, Thompson DC, Diehr P, Koepsell T, Kinne S. 1994. Validity of Self-Reported Smoking: A Review and Meta-analysis. *American Journal of Public Health* 84(7): 1086-1093.

PM3006857398

Source: https://www.industrydocuments.ucsf.edu/docs/tmlx0001

Lange P, Groth S, Nyboe GJ, et al. 1989. Effects of smoking and changes in smoking habits on the decline of FEV1. *Eur Respir J* 2(9):811-6.

Lassila R, Seyberth HW, Haapanen A, Schweer H, Koskenvuo M, Laustiola KE. 1988. Vasoactive and atherogenic effects of cigarette smoking: a study of monozygotic twins discordant for smoking. *BMJ* 297(6654):955-7.

Law MR, Morris JK, Watt HC, Wald NJ. 1997. The dose-response relationship between cigarette consumption, biochemical markers and risk of lung cancer. *Br J Cancer* 75(11):1690-3.

Lazarus P, Sheikh SN, Ren Q, et al. 1998. p53, but not p16 mutations in oral squamous cell carcinomas are associated with specific CYP1A1 and GSTM1 polymorphic genotypes and patient tobacco use. *Carcinogenesis* 19(3):509-14.

Lee CK, Brown BG, Reed EA, Coggins CR, Doolittle DJ, Hayes AW. 1993. Ninety-day inhalation study in rats, using aged and diluted sidestream smoke from a reference cigarette: DNA adducts and alveolar macrophage cytogenetics. *Fundam Appl Toxicol* 20(4):393-401.

Lehman TA, Scott F, Seddon M, et al. 1996. Detection of K-ras oncogene mutations by polymerase chain reaction-based ligase chain reaction. *Anal Biochem* 239(2):153-9.

Lerman C, Caporaso N, Audrain J, Main D, Bowman ED, Lockshin B, Boyd NR, Shields PG. 1999. Evidence suggesting the role of specific genetic factors in cigarette smoking. *Health Psychol* 18(1):14-20.

Lerman C, Caporaso N, Main D, Audrain J, Boyd NR, Bowman ED, Shields PG. 1998. Depression and self-medication with nicotine: themodifying influence of the dopa receptor gene. *Health Psychol* 17(1):56-62.

Lerman C, Shields PG, Main D, et al. 1997. Lack of association of tyrosine hydroxylase genetic polymorphism with cigarette smoking. *Pharmacogenetics* 7(6):521-4.

Li D, Wang M, Cheng L, Spitz MR, Hittelman WN, Wei Q. 1996. In vitro induction of benzo(a)pyrene diol epoxide-DNA adducts in peripheral lymphocytes as a susceptibility marker for human lung cancer. *Cancer Res* 56(16):3638-41.

Liu CS, Kao SH, Wei YH. 1997. Smoking-associated mitochondrial DNA mutations in human hair follicles. *Environ Mol Mutagen* 30(1):47-55.

Liu Y, Hernandez AM, Shibata D, Cortopassi GA. 1994. BCL2 translocation frequency rises with age in humans. *Proc Natl Acad Sci U S A* 91(19):8910-4.

Lodovici M, Akpan V, Giovannini L, Migliani F, Dolara P. 1998. Benzo[a]pyrene diol-epoxide DNA adducts and levels of polycyclic aromatic hydrocarbons in autoptic samples from human lungs. *Chem Biol Interact* 116(3):199-212.

Lubin JH, Blot WJ, Berrino F, et al. 1984. Patterns of lung cancer risk according to type of cigarette smoked. *Int J Cancer* 33(5):569-76.

Ludviksdottir D, Blondal T, Franzon M, Gudmundsson TV, Sawe U. 1999. Effects of nicotine nasal spray on atherogenic and thrombogenic factors during smoking cessation. *J Intern Med* 246(1):61-6.

Lunn RM, Helzlsouer KJ, Parshad R, et al. 2000. XPD polymorphisms: effects on DNA repair proficiency. *Carcinogenesis* 21(4):551-5.

Lunn RM, Langlois RG, Hsieh LL, Thompson CL, Bell DA. 1999. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. *Cancer Res* 59(11):2557-61.

Mao L, Lee JS, Kurie JM, et al. 1997. Clonal genetic alterations in the lungs of current and former smokers. *J Natl Cancer Inst* 89(12):857-62.

McCarthy DS, Craig DB, Cherniack RM. 1976. Effect of modification of the smoking habit on lung function. *Am Rev Respir Dis* 114(1):103-13.

McLemore TL, Adelberg S, Liu MC, et al. 1990. Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. *J Natl Cancer Inst* 82(16):1333-9.

Meyer MJ, Bechtold WE. 1996. Protein adduct biomarkers: state of the art. *Environ Health Perspect* 104 Suppl 5:879-82 .

PM3006857399

Source: https://www.industrydocuments.ucsf.edu/docs/tmlx0001

Izzotti A, Rossi GA, Bagnasco M, De Flora S. 1991. Benzo[a]pyrene diolepoxide-DNA adducts in alveolar macrophages of smokers. *Carcinogenesis* 12(7):1281-5.

Jacob P, Yu L, Shulgin AT, Benowitz NL. 1999. Minor tobacco alkaloids as biomarkers for tobacco use: comparison of users of cigarettes, smokeless tobacco, cigars, and pipes. *Am J Public Health* 89(5):731-6.

Jaffe RL, Nicholson WJ, Garro AJ. 1983. Urinary mutagen levels in smokers. *Cancer Lett* 20(1):37-42.

Jahnke GD, Thompson CL, Walker MP, Gallagher JE, Lucier GW, DiAugustine RP. 1990. Multiple DNA adducts in lymphocytes of smokers and nonsmokers determined by 32P-postlabeling analysis. *Carcinogenesis* 11(2):205-11.

James AL, Knuiman MW, Divitini ML, Musk AW, Ryan G, Bartholomew HC. 1999. Associations between white blood cell count, lung function, respiratory illness and mortality: the Busselton Health Study. *Eur Respir J* 13(5):1115-9.

Jin X, Wu X, Roth JA, et al. 1995. Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotype. *Carcinogenesis* 16(9):2205-8.

Jones IM, Moore DH, Thomas CB, Thompson CL, Strout CL, Burkhart-Schultz K. 1993. Factors affecting HPRT mutant frequency in T-lymphocytes of smokers and nonsmokers. *Cancer Epidemiol Biomarkers Prev* 2(3):249-60.

Jorenby DE, Leischow SJ, Nides MA, et al. 1999. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. *N Engl J Med* 340(9):685-91.

Jourenkova-Mironova N, Voho A, Bouchardy C, et al. 1999. Glutathione S-transferase GSTM1, GSTM3, GSTP1 and GSTT1 genotypes and the risk of smoking-related oral and pharyngeal cancers. *Int J Cancer* 81(1):44-8.

Jourenkova N, Reinikainen M, Bouchardy C, Dayer P, Benhamou S, Hirvonen A. 1998. Larynx cancer risk in relation to glutathione S-transferase M1 and T1 genotypes and tobacco smoking. *Cancer Epidemiol Biomarkers Prev* 7(1):19-23.

Kanner RE, Connett JE, Williams DE, Buist AS. 1999. Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disease: the Lung Health Study. *Am J Med* 106(4):410-6.

Kato S, Bowman ED, Harrington AM, Blomeke B, Shields PG. 1995. Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo. *J Natl Cancer Inst* 87(12):902-7.

Kaufman DW, Palmer JR, Rosenberg L, Stolley P, Warshauer E, Shapiro S. 1989. Tar content of cigarettes in relation to lung cancer. *Am J Epidemiol* 129(4):703-11.

Kawajiri K, Eguchi H, Nakachi K, Sekiya T, Yamamoto M. 1996. Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. *Cancer Res* 56(1):72-6.

Kellermann G, Shaw CR, Luyten-Kellerman M. 1973. Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma. *N Engl J Med* 289(18):934-7.

Khoury MJ, Wagener DK. 1995. Epidemiological evaluation of the use of genetics to improve the predictive value of disease risk factors. *Am J Hum Genet* 56(4):835-44.

Kolonen S, Tuomisto J, Puustinen P, Airaksinen MM. 1992a. Effects of smoking abstinence and chain-smoking on puffing topography and diurnal nicotine exposure. *Pharmacol Biochem Behav* 42(2):327-32.

Kolonen S, Tuomisto J, Puustinen P, Airaksinen MM. 1992b. Puffing behavior during the smoking of a single cigarette in a naturalistic environment. *Pharmacol Biochem Behav* 41(4):701-6.

Kouri RE, McKinney CE, Slomiany DJ, Snodgrass DR, Wray NP, McLemore TL. 1982. Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved lymphocytes. *Cancer Res* 42(12):5030-7.

La DK, Swenberg JA. 1996. DNA adducts: biological markers of exposure and potential applications to risk assessment. *Mutat Res* 365(1-3):129-46.

La Vecchia C, Bidoli E, Barra S, et al. 1990. Type of cigarettes and cancers of the upper digestive and respiratory tract. *Cancer Causes Control* 1(1):69-74.

Source: https://www.industrydocuments.ucsf.edu/docs/tmlx0001

Hagmar L, Brogger A, Hansteen IL, et al. 1994. Cancer risk in humans predicted by increased levels of chromosomal aberrations in lymphocytes: Nordic study group on the health risk of chromosome damage. *Cancer Res* 54(11):2919-22.

Hall J, Bresil H, Donato F, et al. 1993. Alkylation and oxidative-DNA damage repair activity in blood leukocytes of smokers and non-smokers. *Int J Cancer* 54(5):728-33.

Harris CC, Hollstein M. 1993. Clinical implications of the p53 tumor-suppressor gene. *N Engl J Med* 329(18):1318-27.

Hartmann A, Blaszyk H, Kovach JS, Sommer SS. 1997. The molecular epidemiology of p53 gene mutations in human breast cancer. *Trends Genet* 13(1):27-33.

Heath AC, Cates R, Martin NG, et al. 1993. Genetic contribution to risk of smoking initiation: comparisons across birth cohorts and across cultures. *J Subst Abuse* 5(3):221-46.

Heath AC, Martin NG. 1993. Genetic models for the natural history of smoking: evidence for a genetic influence on smoking persistence. *Addict Behav* 18(1):19-34.

Hecht SS. 1999. DNA adduct formation from tobacco-specific N-nitrosamines. *Mutat Res* 424(1-2):127-42.

Hecht SS, Carmella SG, Murphy SE, Akerkar S, Brunnemann KD, Hoffmann D. 1993. A tobacco-specific lung carcinogen in the urine of men exposed to cigarette smoke. *N Engl J Med* 329(21):1543-6.

Helbock HJ, Beckman KB, Ames BN. 1999. 8-Hydroxydeoxyguanosine and 8-hydroxyguanine as biomarkers of oxidative DNA damage. *Methods Enzymol* 300:156-66.

Helbock HJ, Beckman KB, Shigenaga MK, et al. 1998. DNA oxidation matters: the HPLC-electrochemical detection assay of 8-oxo-deoxyguanosine and 8-oxo-guanine. *Proc Natl Acad Sci U S A* 95(1):288-93.

Hellerstein MK, Benowitz NL, Neese RA, et al. 1994. Effects of cigarette smoking and its cessation on lipid metabolism and energy expenditure in heavy smokers. *J Clin Invest* 93(1):265-72.

Henning S, Cascorbi I, Munchow B, Jahnke V, Roots I. 1999. Association of arylamine N-acetyltransferases NAT1 and NAT2 genotypes to laryngeal cancer risk. *Pharmacogenetics* 9(1):103-11.

Herning RI, Jones RT, Benowitz NL, Mines AH. 1983. How a cigarette is smoked determines blood nicotine levels. *Clin Pharmacol Ther* 33(1):84-90.

Hill P, Marquardt H. 1980. Plasma and urine changes after smoking different brands of cigarettes. *Clin Pharmacol Ther* 27(5):652-8.

Hofer I, Nil R, Wyss F, Battig K. 1992. The contributions of cigarette yield, consumption, inhalation and puffing behaviour to the prediction of smoke exposure. *Clin Investig* 70(3-4):343-51.

Hoffmann D, Hoffmann I. 1997. The changing cigarette, 1950-1995. *J Toxicol Environ Health* 50(4):307-64.

Hollstein M, Hergenhahn M, Yang Q, Bartsch H, Wang ZQ, Hainaut P. 1999. New approaches to understanding p53 gene tumor mutation spectra. *Mutat Res* 431(2):199-209.

Hou SM, Yang K, Nyberg F, Hemminki K, Pershagen G, Lambert B. 1999. Hprt mutant frequency and aromatic DNA adduct level in non-smoking and smoking lung cancer patients and population controls. *Carcinogenesis* 20(3):437-44.

Hurt RD, Sachs DP, Glover ED, et al. 1997. A comparison of sustained-release bupropion and placebo for smoking cessation. *N Engl J Med* 337(17):1195-202.

International Agency on the Research of Cancer. 1986. *IARC Monographs on the Evaluationof the Carcinogenic Risk of Chemicals to Humans: Tobacco Smoking*. Vol. 38 ed. Lyon, France: IARC.

Ishibe N, Wiencke JK, Zuo ZF, McMillan A, Spitz M, Kelsey KT. 1997. Susceptibility to lung cancer in light smokers associated with CYP1A1 polymorphisms in Mexican- and African-Americans. *Cancer Epidemiol Biomarkers Prev* 6(12):1075-80.

Izzotti A, De Flora S, Petrilli GL, et al. 1995. Cancer biomarkers in human atherosclerotic lesions: detection of DNA adducts. *Cancer Epidemiol Biomarkers Prev* 4(2):105-10.

Source: https://www.industrydocuments.ucsf.edu/docs/tmlx0001

Drin I, Schoket B, Kostic S, Vincze I. 1994. Smoking-related increase in O6-alkylguanine-DNA alkyltransferase activity in human lung tissue. *Carcinogenesis* 15(8):1535-9.

Dunn BP, Vedal S, San RH, et al. 1991. DNA adducts in bronchial biopsies. *Int J Cancer* 48(4):485-92.

Ebert RV, McNabb ME, McCusker KT, Snow SL. 1983. Amount of nicotine and carbon monoxide inhaled by smokers of low-tar, low-nicotine cigarettes. *JAMA* 250(20):2840-2.

EPA (Environmental Protection Agency). 1992. Respiratory Health Effects of Passive Smoking; Lung Cancer and Other Disorders. Washington, DC: EPA.

Farmer PB, Shuker DE. 1999. What is the significance of increases in background levels of carcinogen-derived protein and DNA adducts? Some considerations for incremental risk assessment. *Mutat Res* 424(1-2):275-86.

Fearon ER. 1997. Human cancer syndromes: clues to the origin and nature of cancer. *Science* 278(5340):1043-50.

Fischer S, Spiegelhalder B, Preussmann R. 1989. Influence of smoking parameters on the delivery of tobacco-specific nitrosamines in cigarette smoke--a contribution to relative risk evaluation. *Carcinogenesis* 10(6):1059-66.

Fliss MS, Usadel H, Caballero OL, et al. 2000. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. *Science* 287(5460):2017-9.

Freeman DJ, Griffin BA, Murray E, et al. 1993. Smoking and plasma lipoproteins in man: effects on low-density lipoprotein cholesterol levels and high-density lipoprotein subfraction distribution. *Eur J Clin Invest* 23(10):630-40.

Fulton JE, Shekelle RB. 1997. Cigarette smoking, weight gain, and coronary mortality: results from the Chicago Western Electric Study. *Circulation* 96(5):1438-44.

Fuster V, Chesebro JH, Frye RL, Elveback LR. 1981. Platelet survival and the development of coronary artery disease in the young adult: effects of cigarette smoking, strong family history and medical therapy. *Circulation* 63(3):546-51.

Gealy R, Zhang L, Siegfried JM, Luketich JD, Keohavong P. 1999. Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women. *Cancer Epidemiol Biomarkers Prev* 8(4 Pt 1):297-302.

Geneste O, Camus AM, Castegnaro M, et al. 1991. Comparison of pulmonary DNA adduct levels, measured by 32P-postlabelling and aryl hydrocarbon hydroxylase activity in lung parenchyma of smokers and ex-smokers. *Carcinogenesis* 12(7):1301-5.

Gilbert DG, Gilbert BO. 1995. Personality, psychopathology, and nicotine response as mediators of the genetics of smoking. *Behav Genet* 25(2):133-47.

Giovino GA. 1999. Epidemiology of tobacco use among US adolescents. *Nicotine Tob Res* 1 Suppl 1:S31-40.

Giovino GA, Henningfield JE, Tomar SL, Escobedo LG, Slade J. Epidemiology of tobacco use and dependence. *Epidemiol Rev* 17(1):48-65.

Grafstrom RC, Dypbukt JM, Sundqvist K, et al. 1994. Pathobiological effects of acetaldehyde in cultured human epithelial cells and fibroblasts. *Carcinogenesis* 15(5):985-90.

Green MS, Harari G. 1995. A prospective study of the effects of changes in smoking habits on blood count, serum lipids and lipoproteins, body weight and blood pressure in occupationally active men. The Israeli CORDIS Study. *J Clin Epidemiol* 48(9):1159-66.

Greenblatt MS, Bennett WP, Hollstein M, Harris CC. 1994. Mutations in the p53 tumor suppressor gene: clues to Cancer etiology and molecular pathogenesis. *Cancer Res* 54(18):4855-78.

Grinberg-Funes RA, Singh VN, Perera FP, et al. 1994. Polycyclic aromatic hydrocarbon-DNA adducts in smokers and their relationship to micronutrient levels and the glutathione-S-transferase M1 genotype. *Carcinogenesis* 15(11):2449-54.

Gritz ER, Rose JE, Jarvik ME. 1983. Regulation of tobacco smoke intake with paced cigarette presentation. *Pharmacol Biochem Behav* 18(3):457-62.

Guengerich FP. 2000. Metabolism of chemical carcinogens. *Carcinogenesis* 21(3):345-51.

Source: https://www.industrydocuments.ucsf.edu/docs/tmlx0001

Bjelogrlic NM, Makinen M, Stenback F, Vahakangas K. 1994. Benzo[a]pyrene-7,8-diol-9,10-epoxide-DNA adducts and increased p53 protein in mouse skin. *Carcinogenesis* 15(4):771-4.

Bonassi S, Abbondandolo A, Camurri L, et al. 1995. Are chromosome aberrations in circulating lymphocytes predictive of future cancer onset in humans? Preliminary results of an Italian cohort study. *Cancer Genet Cytogenet* 79(2):133-5.

Bono R, Russo R, Arossa W, Scursatone E, Gilli G. 1996. Involuntary exposure to tobacco smoke in adolescents: urinary cotinine and environmental factors. *Arch Environ Health* 51(2):127-31.

Brennan JA, Boyle JO, Koch WM, et al. 1995. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. *N Engl J Med* 332(11):712-7.

Bridges RB, Combs JG, Humble JW, Turbek JA, Rehm SR, Haley NJ. 1990. Puffing topography as a determinant of smoke exposure. *Pharmacol Biochem Behav* 37(1):29-39.

Bridges RB, Humble JW, Turbek JA, Rehm SR. 1986. Smoking history, cigarette yield and smoking behavior as determinants of smoke exposure. *Eur J Respir Dis Suppl* 146:129-137.

Brockmoller J, Cascorbi I, Kerb R, Roots I. 1996. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. *Cancer Res* 56(17):3915-25.

Brockmoller J, Cascorbi I, Kerb R, Sachse C, Roots I. 1998. Polymorphisms in xenobiotic conjugation and disease predisposition. *Toxicol Lett* 102-103:173-83.

Bryant MS, Skipper PL, Tannenbaum SR, Maclure M. 1987. Hemoglobin adducts of 4-aminobiphenyl in smokers and nonsmokers. *Cancer Res* 47(2):602-8.

Bryant MS, Vineis P, Skipper PL, Tannenbaum SR. 1988. Hemoglobin adducts of aromatic amines: associations with smoking status and type of tobacco. *Proc Natl Acad Sci U S A* 85(24):9788-91.

Buist AS, Sexton GJ, Nagy JM, Ross BB. 1976. The effect of smoking cessation and modification on lung function. *Am Rev Respir Dis* 114(1):115-22.

Byrd GD, Davis RA, Caldwell WS, Robinson JH, deBethizy JD. 1998. A further study of FTC yield and nicotine absorption in smokers. *Psychopharmacology (Berl)* 139(4):291-9.

Byrd GD, Robinson JH, Caldwell WS, deBethizy JD. 1995. Comparison of measured and FTC-predicted nicotine uptake in smokers. *Psychopharmacology (Berl)* 122(2):95-103.

Carmella SG, Akerkar SA, Richie JP, Hecht SS. 1995. Intraindividual and interindividual differences in metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers' urine. *Cancer Epidemiol Biomarkers Prev* 4(6):635-42.

Carmella SG, Kagan SS, Kagan M, et al. 1990. Mass spectrometric analysis of tobacco-specific nitrosamine hemoglobin adducts in snuff dippers, smokers, and nonsmokers. *Cancer Res* 50(17):5438-45.

Carmelli D, Swan GE, Robinette D, Fabsitz R. 1992. Genetic influence on smoking--a study of male twins. *N Engl J Med* 327(12):829-33.

CDC (Centers for Disease Control and Prevention). 2000. National Health and Nutrition Examination Survey. [Online]. Available: http://www.cdc.gov/nchs/nhanes.htm [accessed 2001].

Cloos J, Braakhuis BJ, Steen I, et al. 1994. Increased mutagen sensitivity in head-and-neck squamous-cell carcinoma patients, particularly those with multiple primary tumors. *Int J Cancer* 56(6):816-9.

Cloos J, Spitz MR, Schantz SP, et al. 1996. Genetic susceptibility to head and neck squamous cell carcinoma. *J Natl Cancer Inst* 88(8):530-5.

Comings DE, Ferry L, Bradshaw-Robinson S, Burchette R, Chiu C, Muhleman D. 1996. The dopamine D2 receptor (DRD2) gene: a genetic risk factor in smoking. *Pharmacogenetics* 6(1):73-9.

Crawford FG, Mayer J, Santella RM, et al. 1994. Biomarkers of environmental tobacco smoke in preschool children and their mothers. *J Natl Cancer Inst* 86(18):1398-402.

Cullen P, Schulte H, Assmann G. 1997. The Munster Heart Study (PROCAM): total mortality in middle-aged men is increased at low total and LDL cholesterol concentrations in smokers but not in non-smokers. *Circulation* 96(7):2128-36.

Djordjevic MV, Stellman SD, Zang E. 2000. Doses of nicotine and lung carcinogens delivered to cigarette smokers. *J Natl Cancer Inst* 92(2):106-11.

PM3006857403

Source: https://www.industrydocuments.ucsf.edu/docs/tmlx0001

REFERENCES

Aguilar F, Harris CC, Sun T, Hollstein M, Cerutti P. 1994. Geographic variation of p53 mutational profile in nonmalignant human liver. *Science* 264(5163):1317-9.

Ahrendt SA, Chow JT, Yang SC, et al. 2000. Alcohol consumption and cigarette smoking increase the frequency of p53 mutations in non-small cell lung cancer. *Cancer Res* 60(12):3155-9.

Ahrendt SA, Halachmi S, Chow JT, et al. 1999. Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. *Proc Natl Acad Sci U S A* 96(13):7382-7.

Ammenheuser MM, Hastings DA, Whorton EB, Ward JB. 1997. Frequencies of hprt mutant lymphocytes in smokers, non-smokers, and former smokers. *Environ Mol Mutagen* 30(2):131-8.

Ashurst SW, Cohen GM, Nesnow S, DiGiovanni J, Slaga TJ. 1983. Formation of benzo(a)pyrene/DNA adducts and their relationship to tumor initiation in mouse epidermis. *Cancer Res* 43(3):1024-9.

Atawodi SE, Lea S, Nyberg F, et al. 1998. 4-Hydroxy-1-(3-pyridyl)-1-butanone-hemoglobin adducts as biomarkers of exposure to tobacco smoke: validation of a method to be used in multicenter studies. *Cancer Epidemiol Biomarkers Prev* 7(9):817-21.

Attardi LD, Jacks T. 1999. The role of p53 in tumour suppression: lessons from mouse models. *Cell Mol Life Sci* 55(1):48-63.

Badawi AF, Hirvonen A, Bell DA, Lang NP, Kadlubar FF. 1995. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. *Cancer Res* 55(22):5230-7.

Bannon MJ, Granneman JG, Kapatos G. 1995. The Dopamine Transporter. Bloom FE, Kupfer DL, ed. *Psychopharmacology: The 4th Generation of Progress*. New York: Raven Press. Pp. 179-188.

Bartsch H, Petruzzelli S, De Flora S, et al. 1991. Carcinogen metabolism and DNA adducts in human lung tissues as affected by tobacco smoking or metabolic phenotype: a case-control study on lung cancer patients. *Mutat Res* 250(1-2):103-14.

Bartsch H, Rojas M, Alexandrov K, et al.1995. Metabolic polymorphism affecting DNA binding and excretion of carcinogens in humans. *Pharmacogenetics* 5 Spec No:S84-90.

Battig K, Buzzi R, Nil R. 1982. Smoke yield of cigarettes and puffing behavior in men and women. *Psychopharmacology (Berl)* 76(2):139-48.

Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW. 1993. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. *J Natl Cancer Inst* 85(14):1159-64.

Bender MA, Awa AA, Brooks AL, et al. 1988. Current status of cytogenetic procedures to detect and quantify previous exposures to radiation. *Mutat Res* 196(2):103-59.

Bennett WP, Hussain SP, Vahakangas KH, Khan MA, Shields PG, Harris CC. 1999. Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer. *J Pathol* 187(1):8-18.

Benowitz NL. 1999. Biomarkers of environmental tobacco smoke exposure. *Environ Health Perspect* 107 Suppl 2:349-55.

Benowitz NL, Hall SM, Herning RI, Jacob P 3d, Jones RT, Osman AL. 1983. Smokers of low-yield cigarettes do not consume less nicotine. *N Engl J Med* 309(3):139-42.

Benowitz NL, Jacob P 3d, Kozlowski LT, Yu L. 1986a. Influence of smoking fewer cigarettes on exposure to tar, nicotine, and carbon monoxide. *N Engl J Med* 315(21):1310-3.

Benowitz NL, Jacob P 3d, Yu L, Talcott R, Hall S, Jones RT. 1986b. Reduced tar, nicotine, and carbon monoxide exposure while smoking ultralow-but not low-yield cigarettes. *JAMA* 256(2):241-6.

Benowitz NL, Zevin S, Jacob P 3rd. 1998. Suppression of nicotine intake during ad libitum cigarette smoking by high-dose transdermal nicotine. *J Pharmacol Exp Ther* 287(3):958-62.

Bishop JM. 1987. The Molecular Genetics of Cancer. *Science* 235:305-311.

PM3006857404

Source: https://www.industrydocuments.ucsf.edu/docs/tmlx0001